ImprimisRx Announces Supply Agreement with iOR Partners

ImprimisRx announced that it has agreed to a product supply agreement with iOR Partners. Under the agreement, ImprimisRx will provide a variety of formulations needed for in-office surgeries, including the MKO Melt and various injectable and topical products.

Financial terms of the deal were not disclosed.

iOR Partners is an innovator in the field of office-based cataract surgery. iOR is growing rapidly, expecting to have 75 office-based cataract surgery suites by the end of next year, accounting for more than 45,000 surgical procedures annually.

“iOR Partners has an exciting business model and we are thrilled to partner with them as they help ophthalmologists make it easier to provide high-quality care to their patients,” John Saharek, President of ImprimisRx, said in a company news release. “In-office surgery is likely where the ophthalmic surgery market is headed, so we’re pleased to provide iOR with the pharmaceutical formulations needed to continue the impressive progress they’re making as they help lead our industry forward.”

Tony Burns, Founder and Partner of iOR Partners, stated, “ImprimisRx is a trusted provider within the ophthalmic community offering a unique suite of formulations not available commercially, and are a natural fit for ophthalmologists looking to provide a more personalized and comfortable patient experience.  Both companies are passionate about helping doctors to improve the patient experience, so we are excited to have ImprimisRx working with us going forward.”